Sign In
Buy GPCR
$48.04
-1.43 (-2.89%)
At Close: Jul 31, 2026
Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate
09:28am, Thursday, 20'th Mar 2025
Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, al
Why Structure Therapeutics Stock Was Stumbling This Week
07:56am, Friday, 14'th Feb 2025
The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics (GPCR 0.16%), was a vi
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
08:30am, Thursday, 30'th Jan 2025
SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
02:53pm, Monday, 06'th Jan 2025
JPMorgan has reset the valuation for Viking Therapeutics Inc. VKTX and Structure Therapeutics Inc. GPCR.
Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans
Structure CEO on the competitive landscape for oral GLP-1 drugs
06:17pm, Thursday, 05'th Dec 2024
Raymond Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk its oral GLP-1 offerings.
Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones
02:10pm, Tuesday, 19'th Nov 2024
A couple of analysts initiated coverage on Septerna, Inc. SEPN, which debuted on NASDAQ last month.
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
08:30am, Friday, 15'th Nov 2024
SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met
Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher do
Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
02:00am, Tuesday, 05'th Nov 2024
Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing ant
Best Momentum Stocks to Buy for October 23rd
11:15am, Wednesday, 23'rd Oct 2024
GPCR, RUSHA and NTRA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 23, 2024.
Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients
02:07pm, Tuesday, 22'nd Oct 2024
Positive 12-week data from phase 2a study of GSBR-1290 targeting obesity patients; significant placebo adjusted mean weight loss of 6.2% & 6.9% achieved for capsule and tablet respectively. One analys
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?
10:56am, Wednesday, 09'th Oct 2024
The consensus price target hints at an 115.8% upside potential for Structure Therapeutics Inc. Sponsored ADR (GPCR). While empirical research shows that this sought-after metric is hardly effective, a
SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for me
Five Top Obesity Stocks to Buy and Hold Long Term
11:50am, Thursday, 12'th Sep 2024
Karl-Hendrik Tittel / Getty Images There's also Altimmune (NASDAQ:ALT), whose pemvidutide treatment led to weight loss while preserving lean mass.
